Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
IL9R Biologics Sequence Review Report 2026: Interleukin-9 receptor Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL9R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL36RN Biologics Sequence Review Report 2026: Interleukin-36 receptor antagonist protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL36RN protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL22RA2 Biologics Sequence Review Report 2026: Interleukin-22 receptor subunit alpha-2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL22RA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL20RB Biologics Sequence Review Report 2026: Interleukin-20 receptor subunit beta Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL20RB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL20RA Biologics Sequence Review Report 2026: Interleukin-20 receptor subunit alpha Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL20RA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL1RL2 Biologics Sequence Review Report 2026: Interleukin-1 receptor-like 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL1RL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL1RL1 Biologics Sequence Review Report 2026: Interleukin-1 receptor-like 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL1RL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL1RAP Biologics Sequence Review Report 2026: Interleukin-1 receptor accessory protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL1RAP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
IL17REL Biologics Sequence Review Report 2026: Interleukin-17 receptor E-like protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL17REL protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL15RA Biologics Sequence Review Report 2026: Interleukin-15 receptor subunit alpha Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL15RA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL11RA Biologics Sequence Review Report 2026: Interleukin-11 receptor subunit alpha Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of IL11RA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGFRL1 Biologics Sequence Review Report 2026: Fibroblast growth factor receptor-like 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFRL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
263
264
265
266
267
>>
1670
>